Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy Volunteers
NCT05201690
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy Subjects
Interventions
DRUG:
VV116 200 mg Group
DRUG:
VV116 400mg Group
DRUG:
VV116 600mg Group
Sponsor
Vigonvita Life Sciences